According to a recent LinkedIn post from Encoded Therapeutics Inc, the company plans to present new clinical and preclinical data at the ASGCT 2026 meeting. The post highlights an oral presentation in the Presidential Symposium on interim safety and efficacy results for ETX101, an investigational AAV9-based gene therapy for SCN1A-positive Dravet syndrome from the POLARIS Phase 1/2 trials.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post also outlines two scientific posters detailing a promoter platform, NociPro, aimed at precise nociceptor targeting for chronic pain, and an AAV-miRNA approach for Angelman syndrome focused on broad neuronal transduction and UBE3A unsilencing. For investors, these appearances suggest continued pipeline advancement in neurological gene therapies and may help validate Encoded’s vector engineering strategy, potentially supporting future partnering interest and valuation if data prove compelling.